

Dr. ADAM FINN

Professor of Paediatrics, Bristol Medical School, UK.

Adam Finn is a Professor of Paediatrics at the Bristol Medical School and honorary consultant in paediatric infectious diseases and immunology at Bristol Royal Hospital for Children. He was chairman of the WHO European Region Technical Advisory Group of Experts (ETAGE) on Immunisation and continues to be a member of the WHO SAGE working group on COVID-19 vaccines. He is a member of the UK NITAG the Joint Committee on Vaccination and Immunisation and several of its subcommittees. He leads the Bristol Vaccine Centre, a clinical trials and translational research group and he coordinates the Bristol University COVID19 Emergency Research (UNCOVER) group.

His **academic journey culminated in a PhD in Immunology**, completed during his tenure as a Lecturer at the Institute of Child Health, Great Ormond Street, London.

In 1992, Professor Finn joined the University of Sheffield as a Senior Lecturer. Over the next nine years, he established both clinical and laboratory research groups, focusing on mucosal immune responses to paediatric conjugate vaccines and the pathogenesis of pneumococcal infections in the upper and lower respiratory tracts.

In 2001, he moved to Bristol, where he now serves as the Theme Leader for Infection & Immunity at the University of Bristol and as the Clinical Research Lead for Children, Genetics, Haematology, Reproductive Health, and Childbirth for the NIHR Clinical Research Network, West of England.

He also holds a **senior clinician position in the paediatric immunology and infectious diseases** clinical service at Bristol Royal Hospital for Children and leads the Bristol Children's Vaccine Centre.

Internationally, Professor Finn has held significant roles, including **Chairman of the WHO European Technical Advisory Group of Experts (ETAGE) on Immunization from 2011 to 2022 and ex officio member of the WHO Strategic Advisory Group of Experts**. He has been a **member of the UK Department of Health Joint Committee on Vaccination and Immunisation (JCVI)** since October 2014.

In 2015, he was elected **President of the European Society for Paediatric Infectious Diseases (ESPID)**.

Professor Adam Finn has authored over **270 peer-reviewed articles**, book chapters, and editorials, contributing significantly to the fields of paediatrics, vaccinology, and infectious diseases. His main research interests revolve around understanding mucosal immune responses to vaccines and how and why they induce indirect effects and how to quantify the burden of vaccine preventable diseases and the effectiveness of vaccines in the field. He also leads and supports numerous clinical trials of drugs and medicines in children and is involved in the development of a novel virus like particle vaccine platform being developed in Bristol.